We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). NEJM - Error
This isnt new. Been out for a while and its a pure EPA fish oil, no dha. What is new is a study that shows Vascepa to reduce the risk of stroke and heart attack by 25% without statins. Adding statin reduces the risk another 25-30%. Its a huge break through and i think the next study with this drug will be about reducing inflammation. This is exciting.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.